Browse the corpus

REFERENCES Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97. Azambuja E, Fleck JF, Batista RG, et al, “Bleomycin Lung Toxicity: Who are the Patients With Increased Risk?” Pulm Pharmacol Ther , 2005, 18(5):363-66. [PubMed 15939315 ] Carver JR, Shapiro CL, Ng A, et al, “American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects,” J Clin Oncol , 2007, 25(25):3991-4008. [PubMed 17577017 ] Culine S, Kramar A, Théodore C, et al, “Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP,” J Clin Oncol , 2008, 26(3):421-7. [PubMed 18202419 ] Cushing B, Giller R, Cullen JW, et al, “Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study -- Pediatric Oncology Group 9049 and Children's Cancer Group 8882,” J Clin Oncol , 2004, 22(13):2691-700. [PubMed 15226336 ] Dann EJ, Bar-Shalom R, Tamir A, et al, “Risk-Adapted BEACOPP Regimen Can Reduce the Cumulative Dose of Chemotherapy for Standard and High-Risk Hodgkin Lymphoma With No Impairment of Outcome,” Blood , 2007, 109(3):905-9. [PubMed 17018856 ] Diehl V, Franklin J, Pfreundschuh M, et al, “Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,” N Engl J Med , 2003, 348(24):2386-95. [PubMed 12802024 ] Engert A, Franklin J, Eich HT, et al, “Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial,” J Clin Oncol , 2007, 25(23):3495-502. [PubMed 17606976 ] Floyd JD, Nguyen DT, Lobins RL, et al, “Cardiotoxicity of Cancer Therapy,” J Clin Oncol , 2005, 23(30):7685-96. [PubMed 16234530 ]

Engert A, Franklin J, Eich HT, et al, “Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial,” J Clin Oncol , 2007, 25(23):3495-502. [PubMed 17606976 ] Floyd JD, Nguyen DT, Lobins RL, et al, “Cardiotoxicity of Cancer Therapy,” J Clin Oncol , 2005, 23(30):7685-96. [PubMed 16234530 ] Griggs JJ, Mangu PB, Anderson H, et al, “Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,” J Clin Oncol , 2012, 30(13):1553-61. [PubMed 22473167 ] Horning SJ, Hoppe RT, Breslin S, et al, “Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,” J Clin Oncol , 2002, 20(3):630-7. [PubMed 11821442 ] Horning SJ, Williams J, Bartlett NL, et al, “Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,” J Clin Oncol , 2000, 18(5):972-80. [PubMed 10694546 ] Hoskin PJ, Lowry L, Horwich A, et al, “Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244,” J Clin Oncol , 2009, 27(32):5390-6. [PubMed 19738111 ] Huang TT, Hudson MM, Stokes DC, et al, “Pulmonary Outcomes in Survivors of Childhood Cancer: A Systematic Review,” Chest , 2011, 140(4): 881-901. [PubMed 21415131 ] Hutchinson RJ, Fryer CJ, Davis PC, et al, “MOPP or Radiation in Addition to ABVD in the Treatment of Pathologically Staged Advanced Hodgkin's Disease in Children: Results of the Children's Cancer Group Phase III Trial,” J Clin Oncol , 1998, 16(3):897-906. [PubMed 9508171 ] Ibrahimi OA and Anderson RR, “Images in Clinical Medicine. Bleomycin-Induced Flagellate Hyperpigmentation,” N Engl J Med , 2010, 363(24):e36. [PubMed 21142531 ] Johnson PW, Radford JA, Cullen MH, et al, “Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519),” J Clin Oncol , 2005, 23(36):9208-18. [PubMed 16314615 ]

Ibrahimi OA and Anderson RR, “Images in Clinical Medicine. Bleomycin-Induced Flagellate Hyperpigmentation,” N Engl J Med , 2010, 363(24):e36. [PubMed 21142531 ] Johnson PW, Radford JA, Cullen MH, et al, “Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519),” J Clin Oncol , 2005, 23(36):9208-18. [PubMed 16314615 ] King PD and Perry MC, “Hepatotoxicity of Chemotherapy,” Oncologist , 2001, 6(2):162-76. [PubMed 11306728 ] Kintzel PE and Dorr RT, “Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,” Cancer Treat Rev , 1995, 21(1):33-64. [PubMed 7859226 ] Kung FH, Schwartz CL, Ferree CR,et al, “POG 8625: A Randomized Trial Comparing Chemotherapy With Chemoradiotherapy for Children and Adolescents With Stages I, IIA, IIIA1 Hodgkin Disease: A Report From the Children's Oncology Group,” J Pediatr Hematol Oncol , 2006, 28(6):362-8. [PubMed 16794504 ] Lam MS, “The Need for Routine Bleomycin Test Dosing in the 21st Century,” Ann Pharmacother , 2005, 39(11):1897-902. [PubMed 16219896 ] Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” Lancet Oncol , 2011, 12(8):806-14. [PubMed 21276754 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Nichols CR, Catalano PJ, Crawford ED, et al, “Randomized Comparison of Cisplatin and Etoposide and Either Bleomycin or Ifosfamide in Treatment of Advanced Disseminated Germ Cell Tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study,” J Clin Oncol , 1998, 16(4):1287-93. [PubMed 9552027 ] O'Sullivan JM, Huddart RA, Norman AR, et al, “Predicting the Risk of Bleomycin Lung Toxicity in Patients With Germ-Cell Tumours,” Ann Oncol , 2003, 14(1):91-6. [PubMed 12488299 ] Sleijfer S, “Bleomycin-Induced Pneumonitis,” Chest , 2001, 120(2):617-24. [PubMed 11502668 ]

Nichols CR, Catalano PJ, Crawford ED, et al, “Randomized Comparison of Cisplatin and Etoposide and Either Bleomycin or Ifosfamide in Treatment of Advanced Disseminated Germ Cell Tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study,” J Clin Oncol , 1998, 16(4):1287-93. [PubMed 9552027 ] O'Sullivan JM, Huddart RA, Norman AR, et al, “Predicting the Risk of Bleomycin Lung Toxicity in Patients With Germ-Cell Tumours,” Ann Oncol , 2003, 14(1):91-6. [PubMed 12488299 ] Sleijfer S, “Bleomycin-Induced Pneumonitis,” Chest , 2001, 120(2):617-24. [PubMed 11502668 ] Straus DJ, Portlock CS, Qin J, et al, “Results of aPprospective Randomized Clinical Trial of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Followed by Radiation Therapy (RT) Versus ABVD Alone for stages I, II, and IIIA Nonbulky Hodgkin Disease,” Blood , 2004, 104(12):3483-9. [PubMed 15315964 ] Tobias JS, Monson K, Gupta N, et al, “Chemoradiotherapy for Locally Advanced Head and Neck Cancer: 10-year Follow-Up of the UK Head and Neck (UKHAN1) Trial,” Lancet Oncol , 2010, 11(1):66-74. [PubMed 19875337 ] Wiernik PH, Hong F, Glick JH, et al, “Radiation Therapy Compared With Chemotherapy for Consolidation of Chemotherapy-Induced Remission of Advanced Hodgkin Lymphoma: A Study by the Eastern Co-Operative Oncology Group (E1476) With >20 Years Follow-Up,” Leuk Lymphoma , 2009, 50(10):1632-41. [PubMed 19863338 ] Williams S, Blessing JA, Liao SY, et al, “Adjuvant Therapy of Ovarian Germ Cell Tumors With Cisplatin, Etoposide, and Bleomycin: A Trial of the Gynecologic Oncology Group,” J Clin Oncol , 1994, 12(4):701-6. [PubMed 7512129 ] Topic 9160 Version 42.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]